Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Multiplace Series
Hard-Shell Multiplace·2-18+ person
Pressure3 ATA
$150,000 - $400,000+
●●○○Emerging Evidence
Hyperbaric Therapy for Cerebral Palsy
The most-studied pediatric HBOT indication — with a landmark Lancet RCT that produced surprising results and ongoing scientific debate.
Hyperbaric oxygen therapy (HBOT) for Cerebral Palsy has emerging clinical evidence. This is currently an off-label use and is not covered by insurance. The recommended protocol is 1.3–1.75 ATA ATA for 60 minutes per session per session over 40 sessions sessions.
Key Takeaways
- Collet et al. (2001) Lancet RCT: both treatment (1.75 ATA O2) and sham (1.3 ATA air) groups improved significantly — sparking ongoing scientific debate
- Most-studied pediatric HBOT indication with 20+ years of research
- Theoretical basis: 'idling neurons' in CP injury penumbra may recover function with enhanced oxygen delivery
- Younger children hypothesized to respond better due to greater neuroplasticity
- Motor function, speech, attention, and behavior improvements reported across multiple uncontrolled studies
What is Cerebral Palsy?
Cerebral palsy (CP) is a group of permanent movement and posture disorders caused by non-progressive damage to the developing brain, typically occurring before, during, or shortly after birth. It is the most common cause of childhood physical disability. The brain injury in CP — whether from hypoxia, infarction, or hemorrhage — leaves zones of damaged but potentially partially functional neurons, particularly in border regions around the primary injury site. Hyperbaric oxygen therapy for cerebral palsy is the most extensively studied pediatric HBOT application. The theoretical basis is compelling: if neurons in the injury penumbra are hypoperfused but not dead — sometimes called 'idling neurons' — then dramatically increasing oxygen delivery might restore partial function. This hypothesis has driven a substantial research program, including the landmark 2001 Lancet trial. The evidence picture is genuinely complex and contested. The most important RCT (Collet et al., 2001) produced a surprising result: both the treatment group (1.75 ATA + 100% O2) and the sham group (1.3 ATA + ambient air) improved significantly — but there was no significant difference between them. This finding has been interpreted in multiple ways: as evidence that HBOT doesn't work beyond placebo, or as evidence that even mild hyperbaric pressure (1.3 ATA with air) provides benefit. Families and some clinicians remain strong advocates based on individual outcome reports.
How Hyperbaric Therapy Helps Cerebral Palsy
The primary hypothesis is activation of dormant 'idling neurons' in the penumbra zones of the cerebral palsy brain injury. These neurons have reduced metabolic activity due to chronic mild hypoperfusion — they are alive but not functioning optimally. Hyperoxic conditions dramatically increase dissolved oxygen in cerebrospinal fluid and brain tissue, potentially restoring metabolic activity in these cells. Additional proposed mechanisms include: reduction of neuroinflammation (particularly relevant in CP where ongoing inflammatory signaling may impair development), promotion of neuroplasticity through growth factor upregulation (VEGF, BDNF), and improved myelination of developing neural pathways. The pediatric brain's greater neuroplasticity compared to adults may make these mechanisms more accessible — which is why earlier intervention is generally hypothesized to produce better results.
Recommended Protocol
Pressure
1.3–1.75 ATA
Sessions
40 sessions
Duration
60 minutes per session
What Does the Evidence Say?
●●○○Emerging Evidence
Collet et al. (2001) published the pivotal RCT in The Lancet: 111 children with CP randomized to 1.75 ATA + 100% O2 vs. 1.3 ATA + 21% air (intended sham). Both groups showed significant improvement in gross motor function, attention, and memory. The lack of between-group difference raised the possibility that 1.3 ATA air is not truly an inert sham — the study's own authors acknowledged this. Muller-Bolla et al. (2006) conducted a meta-analysis that found insufficient evidence to recommend HBOT as standard treatment but noted improvement trends. Multiple subsequent uncontrolled studies and case series have reported meaningful improvements in motor function, speech, and cognition. The field is limited by: small sample sizes, heterogeneity of CP types, challenge of creating true sham conditions in pediatric HBOT trials, and the high cost creating selection bias in who receives treatment.
Off-Label Use
Cerebral Palsy is not an FDA-approved indication for HBOT. Treatment is considered off-label and is typically not covered by insurance. Consult your physician before starting any HBOT protocol.
Recommended Chambers for Cerebral Palsy
Based on the protocol requirements — minimum 1.3 ATA, Clinical Grade or Advanced Wellness tier. Sorted by clinical credibility score.
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 34
Hard-Shell Monoplace·1-person
Pressure3 ATA
$50,000 - $90,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 36
Hard-Shell Monoplace·1-person
Pressure3 ATA
$55,000 - $95,000
Clinical GradeFDA Cleared
For Maximum Comfort
Perry Baromedical
Sigma 40
Hard-Shell Monoplace·1-person
Pressure3 ATA
$65,000 - $110,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 40-II
Hard-Shell Multiplace·2-person
Pressure3 ATA
$100,000 - $160,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma Elite
Hard-Shell Monoplace·1-person
Pressure3 ATA
$80,000 - $130,000
Frequently Asked Questions
What did the Collet 2001 Lancet trial actually show — did HBOT work or not?
Both groups improved significantly — including the 'sham' group receiving 1.3 ATA with air. There was no statistically significant difference between groups. This is the key controversy: the study authors and some experts concluded HBOT showed no specific benefit beyond sham. Others argue the sham wasn't truly inert — 1.3 ATA with enriched air still delivers somewhat elevated oxygen — and that both groups benefiting suggests mild hyperbaric pressure itself has therapeutic value. The honest answer is that the trial did not establish HBOT's superiority over a mild pressurization comparator, and designing a true inert placebo for HBOT is genuinely difficult.
What age is most likely to benefit — are adults with CP candidates?
The research focus has been on children, where neuroplasticity is highest. Most HBOT for CP studies involve children aged 3–12. The rationale for earlier intervention is stronger because the brain is still developing and may be more responsive to oxygen-mediated neuroplasticity signals. Adult CP patients may still benefit — particularly for symptoms like spasticity, pain, and functional mobility — but the evidence base is almost entirely pediatric. There is no age cutoff at which HBOT is contraindicated for CP, but expectations should be calibrated to the available data.
How do families typically access HBOT for cerebral palsy?
Most families seek HBOT through private hyperbaric clinics specializing in neurological conditions or pediatric HBOT. Some hospital hyperbaric units will see CP patients off-label with physician referral. The cost is a significant barrier — 40 sessions at $150–$350 per session totals $6,000–$14,000, not covered by insurance. Some families have raised funds specifically for HBOT. A small number of research trials have offered free treatment. The CP community has active advocacy groups that maintain lists of clinics with CP experience.
Can a child use a hyperbaric chamber safely?
Yes — pediatric HBOT has a well-established safety profile at the pressures used for CP (1.3–1.75 ATA). Children must be accompanied in multiplace chambers or have adult supervision. The main considerations are ear equalization (young children may need sedation or tympanostomy tubes to handle pressure changes), claustrophobia management, and ensuring the child can communicate any discomfort. Experienced pediatric HBOT centers have protocols for children. Mild monoplace chambers are also used with a parent present or visible outside.
What improvements are most commonly reported in CP after HBOT?
Parents and clinicians most commonly report improvements in: gross motor function (walking, coordination), fine motor skills, attention and focus, speech and communication, behavior, and sleep. The Collet trial measured gross motor function, attention, and memory — all improved in both groups. Individual case reports and uncontrolled studies describe improvements across a broad range of developmental domains. The heterogeneity of CP types makes it difficult to predict which children will respond best.
Related Conditions
Sources & References
- Collet et al. (2001) — Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial, The Lancet
- Muller-Bolla et al. (2006) — Systematic review of hyperbaric oxygen therapy in cerebral palsy, Developmental Medicine & Child Neurology
- Lippert-Grüner et al. (2006) — Hyperbaric oxygen therapy in the treatment of cerebral palsy, Neurological Research
- Lacey et al. (2012) — A systematic review of the evidence for hyperbaric oxygen therapy in children with cerebral palsy, Developmental Medicine & Child Neurology
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Ready to compare chambers?
Use our filterable directory to find chambers that match your protocol requirements.